AsclepiX Therapeutics, Inc., is a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases. AXT107, an investigational lead clinical candidate, has a unique mechanism of action that targets two proven pathways of diseases of the retina and is poised to enter the clinic in late 2020.